Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate
Denosumab May Help Prevent Bone Loss
Past Highlights
Results:
1 -10 of 48
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
7/26/2005
 
First Published:
4/23/2003
1.
Phase II/III Randomized Study of CC-5013 in Patients With Progressive or Relapsed Metastatic Malignant Melanoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0210051
CELGENE-CDC-501-MEL-001, MSKCC-03026, NCT00060281
Last Modified:
6/13/2008
 
First Published:
6/23/2003
2.
Phase III Randomized Study of Dexamethasone With or Without Lenalidomide in Patients With Previously Untreated Stage I, II, or III Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI
SWOG-S0232
S0232, NCT00064038
3.
Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
Pharmaceutical / Industry
CC-5013-MEL-002
NCT00057616
4.
Study of Bortezomib and Revlimidâ„¢ for Patients Relapsing or Progressing on Total Therapy II
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
18 and over
Other
UARK 2003-35
NCT00093028
Last Modified:
7/21/2008
 
First Published:
11/22/2004
5.
Phase III Randomized Study of Lenalidomide With Standard-Dose Versus Low-Dose Dexamethasone With or Without Salvage Therapy Comprising Thalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
NCI
ECOG-E4A03
E4A03, NCT00098475
6.
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q- Abnormality
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
CC-5013-MDS-004
NCT00179621
7.
A Multicentre, Single-Arm, Open-Label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
CC-5013-MM-018
NCT00420849
8.
CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 and over
Pharmaceutical / Industry
CC-5013-MM-009
NCT00056160
9.
A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Not specified
Pharmaceutical / Industry
CC-5013-MM-010
NCT00424047
10.
Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
18 and over
Pharmaceutical / Industry
CC-5013-OVRY-002
NCT00179712
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute